Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear. The Company has developed a proprietary technology that is designed to deliver a drug that is retained in the ear for an extended period of time following a single local administration. Utilizing this technology, Otonomy has advanced multiple product candidates into development and launched its first product, OTIPRIO®.

OTIPRIO is a single-dose, physician-administered antibacterial and the first product approved by the FDA for the treatment of pediatric patients with bilateral otitis media with effusion undergoing ear tube placement.

San Diego, US
Size (employees)
139 (est)
Otonomy was founded in 2008 and is headquartered in San Diego, US
Report incorrect company information

Key People/Management at Otonomy

Paul Cayer

Paul Cayer

Chief Financial and Business Officer

Otonomy Office Locations

Otonomy has an office in San Diego
San Diego, US (HQ)
6275 Nancy Ridge Dr
Show all (1)
Report incorrect company information

Otonomy Financials and Metrics

Otonomy Financials

Otonomy's revenue was reported to be $683 k in FY, 2016

Revenue (Q2, 2017)

326 k

Gross profit (Q2, 2017)

(71 k)

Gross profit margin (Q2, 2017), %


Net income (Q2, 2017)

(23.2 m)

EBIT (Q2, 2017)

(23.5 m)

Market capitalization (5-Mar-2018)

153 m

Cash (1-Mar-2018)

24.2 m
Otonomy's current market capitalization is $153 m.
USDFY, 2014FY, 2015FY, 2016


683 k

Cost of goods sold

1.7 m

Gross profit

(981 k)

Gross profit Margin, %

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


13 k76 k321 k358 k326 k

Cost of goods sold

9 k395 k351 k463 k397 k

Gross profit

4 k(319 k)(30 k)(105 k)(71 k)

Gross profit Margin, %

USDFY, 2014FY, 2015FY, 2016


139.8 m158.7 m24.2 m

Accounts Receivable

91 k


1.6 b5.3 m1.4 m

Current Assets

157.7 m188.2 m202.2 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(42.9 m)(61.7 m)(110.6 m)

Depreciation and Amortization

213 k358 k708 k


(1.4 m)

Accounts Payable

(309 k)1.7 m(2.2 m)
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(29.7 m)(27.6 m)(27.1 m)


614 k913 k1.7 m1.2 m1.2 m

Accounts Payable

1.7 m1.9 m4 k2.1 m2.4 m800 k934 k212 k1.3 m
Show all financial metrics

Otonomy Operating Metrics

FY, 2016

Patents Issued


Patents Pending


Phase I Trials


Phase II Trials

Show all operating metrics
Report incorrect company information

Otonomy News and Updates

Ultimate Analysis on Meniere ’s disease Market & Global Forecast to 2023

Meniere’s disease market Analysis, by diagnosis (hearing assessment, balance assessment, and others), by treatment (medication, surgery, and others), by end user & is to Grow with USD 6380.3 Million, 8.5% of CAGR Posted via Industry Today. Follow us on Twitter @IndustryToday

Magnificent Expansion of Meniere ’s disease Market: Valuation USD 6380.3 Million, 8.5% of CAGR By 2023

Market Research Future published a research report on “Meniere’s Disease Market Research Report- Global Forecast till 2023“– Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information